|MDACC Study No:||2008-0075 (clinicaltrials.gov NCT No: NCT00603668)|
|Title:||A Phase I/II Study of Immunotherapy with Milatuzumab (hLL1) in Patients with Non-Hodgkin’s Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)|
|Principal Investigator:||Felipe Samaniego|
|Study Description:||The goal of the Phase I part of this clinical research study is to find the |
highest tolerable dose of milatuzumab that can be given to patients with NHL or
The goal of the Phase II part of this clinical research study is to learn if
milatuzumab can help to control NHL or CLL. The safety of the study drug will
also be studied.